Adam J Walker
Overview
Explore the profile of Adam J Walker including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
47
Citations
670
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Varela R, Macpherson H, Walker A, Houghton T, Yates C, Yates N, et al.
Brain Behav Immun
. 2025 Mar;
127:170-182.
PMID: 40064431
Inflammation and metabolic dysfunction impair dopamine neurotransmission, which is thought to serve as a critical mechanism underpinning motivational deficits such as anhedonia across a range of psychiatric and neurological disorders....
2.
Bastawy E, Eraslan I, Voglsanger L, Suphioglu C, Walker A, Dean O, et al.
Int J Mol Sci
. 2024 Jul;
25(13).
PMID: 39000495
Patients with asthma experience elevated rates of mental illness. However, the molecular links underlying such lung-brain crosstalk remain ambiguous. Hypothalamic dysfunction is observed in many psychiatric disorders, particularly those with...
3.
Lotfaliany M, Agustini B, Walker A, Turner A, Wrobel A, Williams L, et al.
Aust N Z J Psychiatry
. 2024 Jun;
58(8):656-667.
PMID: 38845137
Objective: Harmonized tools are essential for reliable data sharing and accurate identification of relevant factors in mental health research. The primary objective of this study was to create a harmonized...
4.
Eraslan I, Egberts-Brugman M, Read J, Voglsanger L, Samarasinghe R, Hamilton L, et al.
Biochem Pharmacol
. 2024 May;
225:116265.
PMID: 38714277
Relaxin-family peptide 3 receptor (RXFP3) is activated by relaxin-3 in the brain to influence arousal and related functions, such as feeding and stress responses. Two transgenic mouse lines have recently...
5.
Berk M, Kohler-Forsberg O, Turner M, Penninx B, Wrobel A, Firth J, et al.
World Psychiatry
. 2023 Sep;
22(3):366-387.
PMID: 37713568
Populations with common physical diseases - such as cardiovascular diseases, cancer and neurodegenerative disorders - experience substantially higher rates of major depressive disorder (MDD) than the general population. On the...
6.
Panizzutti B, Skvarc D, Lin S, Croce S, Meehan A, Bortolasci C, et al.
Int J Mol Sci
. 2023 Mar;
24(6).
PMID: 36982324
Minocycline has anti-inflammatory, antioxidant, and anti-apoptotic properties that explain the renewed interest in its use as an adjunctive treatment for psychiatric and neurological conditions. Following the completion of several new...
7.
Walker A, Mohebbi M, Maes M, Berk M, Walder K, Bortolasci C, et al.
Brain Behav Immun Health
. 2023 Jan;
27:100581.
PMID: 36632339
Background: Adjunctive minocycline shows promise in treating affective and psychotic disorders; however, the therapeutic mechanism remains unclear. Identifying relevant biomarkers may enhance the efficacy of novel adjunctive treatment candidates. We...
8.
Dean O, Walker A
Eur Neuropsychopharmacol
. 2022 Nov;
66:11-13.
PMID: 36335679
No abstract available.
9.
Dodd S, Sominsky L, Siskind D, Bortolasci C, Carvalho A, Maes M, et al.
Eur Neuropsychopharmacol
. 2022 Oct;
64:32-43.
PMID: 36191545
Advances in psychopharmacology have been significantly slower to evolve than in other disciplines of medicine and therefore investigation into novel therapeutic approaches is required. Additionally, concurrent metabolic conditions are prevalent...
10.
Hasebe K, Mohebbi M, Gray L, Walker A, Bortolasci C, Turner A, et al.
Acta Neuropsychiatr
. 2021 Dec;
34(4):220-227.
PMID: 34937590
This study aimed to explore effects of adjunctive minocycline treatment on inflammatory and neurogenesis markers in major depressive disorder (MDD). Serum samples were collected from a randomised, placebo-controlled 12-week clinical...